EAACI: A European Declaration on Immunotherapy. Designing the future of allergen specific immunotherapy.
EAACI: A European Declaration on Immunotherapy. Designing the future of allergen specific immunotherapy.
复制标题
EAACI：欧洲免疫疗法宣言。设计过敏原特异性免疫疗法的未来。
DOI：
10.1186/2045-7022-2-20
复制
发表时间：
2012-10-30
影响因子：
4.4
通讯作者：
Papadopoulos N
中科院分区：
文献类型：
--
作者：
Calderon MA;Demoly P;Gerth van Wijk R;Bousquet J;Sheikh A;Frew A;Scadding G;Bachert C;Malling HJ;Valenta R;Bilo B;Nieto A;Akdis C;Just J;Vidal C;Varga EM;Alvarez-Cuesta E;Bohle B;Bufe A;Canonica WG;Cardona V;Dahl R;Didier A;Durham SR;Eng P;Fernandez-Rivas M;Jacobsen L;Jutel M;Kleine-Tebbe J;Klimek L;Lötvall J;Moreno C;Mosges R;Muraro A;Niggemann B;Pajno G;Passalacqua G;Pfaar O;Rak S;Senna G;Senti G;Valovirta E;van Hage M;Virchow JC;Wahn U;Papadopoulos N
今天，过敏是一个大流行级别的公共卫生问题，仅在欧洲就影响到1.5亿多人。鉴于流行病学趋势，欧洲过敏和临床免疫学会(EAACI)预测，在未来几十年内，超过一半的欧洲人口可能会在一生中的某个时候经历某种类型的过敏。过敏患者不仅患有一种使人衰弱的疾病，有可能对他们的生活质量、职业发展、个人发展和生活方式选择产生重大影响，而且由于生产力下降和表现不佳的日子，他们还构成了卫生经济学和宏观经济学的重大负担。鉴于包括城市化、工业化、污染和气候变化在内的过敏诱因在可预见的未来预计不会改变，因此必须采取步骤制定、加强和优化预防和治疗战略。过敏原特异性免疫疗法是目前唯一有可能影响疾病自然病程的医学干预措施。多年的基础科学研究、临床试验、系统综述和荟萃分析令人信服地表明，过敏原特异性免疫疗法可以为患者取得实质性的效果，改善过敏者的生活质量，降低过敏症的长期成本和负担，并改变疾病的进程。变应原特异性免疫疗法不仅有效缓解过敏症状，而且在治疗结束后具有长期疗效，可以防止变态反应性疾病的进展。不幸的是，过敏原特异性免疫疗法尚未得到包括研究资助机构在内的欧洲机构的足够重视，尽管这可能是一个在投资回报、翻译价值和欧洲一体化方面最有回报的领域，欧洲在这一领域被公认为全球领先者。仍然缺乏对过敏性疾病的全部成本的评估和监测，欧洲各地的各种卫生系统正在扼杀进一步的进展。这意味着普通人群仍然不知道过敏原特异性免疫疗法的潜在用途及其潜在的好处。我们呼吁欧洲政策制定者协调行动，通过以下方式改善个人和公共健康：提高对过敏原特异性免疫疗法有效性的认识，更新国家医疗政策，支持过敏原特异性免疫疗法，优先资助过敏原特异性免疫疗法研究，监测过敏的宏观经济参数和卫生经济参数，加强医学学科和专业的过敏教学上述政策的有效实施有可能在未来十年对欧洲的健康和福祉产生重大积极影响。
Allergy today is a public health concern of pandemic proportions, affecting more than 150 million people in Europe alone. In view of epidemiological trends, the European Academy of Allergy and Clinical Immunology (EAACI) predicts that within the next few decades, more than half of the European population may at some point in their lives experience some type of allergy. Not only do allergic patients suffer from a debilitating disease, with the potential for major impact on their quality of life, career progression, personal development and lifestyle choices, but they also constitute a significant burden on health economics and macroeconomics due to the days of lost productivity and underperformance. Given that allergy triggers, including urbanization, industrialization, pollution and climate change, are not expected to change in the foreseeable future, it is imperative that steps are taken to develop, strengthen and optimize preventive and treatment strategies. Allergen specific immunotherapy is the only currently available medical intervention that has the potential to affect the natural course of the disease. Years of basic science research, clinical trials, and systematic reviews and meta-analyses have convincingly shown that allergen specific immunotherapy can achieve substantial results for patients, improving the allergic individuals’ quality of life, reducing the long-term costs and burden of allergies, and changing the course of the disease. Allergen specific immunotherapy not only effectively alleviates allergy symptoms, but it has a long-term effect after conclusion of the treatment and can prevent the progression of allergic diseases. Unfortunately, allergen specific immunotherapy has not yet received adequate attention from European institutions, including research funding bodies, even though this could be a most rewarding field in terms of return on investments, translational value and European integration and, a field in which Europe is recognized as a worldwide leader. Evaluation and surveillance of the full cost of allergic diseases is still lacking and further progress is being stifled by the variety of health systems across Europe. This means that the general population remains unaware of the potential use of allergen specific immunotherapy and its potential benefits. We call upon Europe’s policy-makers to coordinate actions and improve individual and public health in allergy by: Promoting awareness of the effectiveness of allergen specific immunotherapy Updating national healthcare policies to support allergen specific immunotherapy Prioritising funding for allergen specific immunotherapy research Monitoring the macroeconomic and health economic parameters of allergy Reinforcing allergy teaching in medical disciplines and specialties The effective implementation of the above policies has the potential for a major positive impact on European health and well-being in the next decade.